{"topic_id":"owner_education_dirlotapide_plain","category":"owner-education","context":"---\ntopic_id: owner_education_dirlotapide_plain\ncategory: owner-education\ntitle: \"Plain-language: Dirlotapide (Slentrol), the dog weight-loss drug — withdrawn in the EU, still on the US record (EN+ZH)\"\nlang: en\nsource: \"Derived from dirlotapide-withdrawal-ade article (C1-verified source topics)\"\nsource_file: web/articles/articles/dirlotapide-withdrawal-ade.md\ndate_parsed: 2026-08-16\ntokens_estimated: 340\nverified: true\nverification: derived\nsource_document: \"Dirlotapide withdrawal and US adverse-event record — plain-language owner summary\"\ncitation:\n  authority: \"FDA CVM openFDA / EMA (via source article)\"\n  title: \"Dirlotapide withdrawal and US adverse-event record — plain-language owner summary\"\n  url: \"\"\n  retrieved: \"2026-08-16\"\n  ref: \"derived from dirlotapide-withdrawal-ade\"\n  doc_type: \"derived plain-language summary\"\n  needs_review: false\nlicense: derived\n---\n\n**EN — For dog owners.** Dirlotapide is the active ingredient in `Slentrol (dirlotapide) — EMEA/V/C/000116`, a canine weight-loss medicine whose indication was `As an aid in the management of overweight and obesity in adult dogs`. In the EU its status is now `Status: Withdrawn`. But in the US FDA adverse-event database the molecule still shows `Dirlotapide: 2994` reports, with top reported reactions including `Vomiting 927`. Two cautions: the counts are `CUMULATIVE as of openFDA pull 2026-07-22`, and `\"Lack of efficacy\" terms denote product-performance reports, not adverse reactions`. Most important: `reported ≠ causal` — a report does not prove the drug caused the event. Bottom line — the drug is off the EU market; its US report file stays on the books.\n\n**中文 — 给养狗主人。** Dirlotapide 是犬用减肥药 `Slentrol (dirlotapide) — EMEA/V/C/000116` 的有效成分，适应症为`帮助管理成年犬超重与肥胖`（原文：`As an aid in the management of overweight and obesity in adult dogs`）。它在欧盟的状态是 `Status: Withdrawn`（已撤市）。但在美国 FDA 不良事件数据库里仍有 `Dirlotapide: 2994` 条报告，最多报告的反应含 `Vomiting 927`（呕吐 927 例）。两点注意：计数是 `CUMULATIVE as of openFDA pull 2026-07-22`（累计快照）；且`\"缺乏疗效\"类术语是产品性能报告，不是不良反应`（`\"Lack of efficacy\" terms denote product-performance reports, not adverse reactions`）。最重要：`reported ≠ causal`（有报告 ≠ 有因果）。结论——药已在欧盟撤市，但美国的报告档案仍在。\n\nSource article: `dirlotapide-withdrawal-ade` (built from C1-verified openFDA / EMA source topics).\n\n## Claims (verified as substrings of the C1-verified source article)\n- `Slentrol (dirlotapide) — EMEA/V/C/000116`\n- `As an aid in the management of overweight and obesity in adult dogs`\n- `Status: Withdrawn`\n- `Dirlotapide: 2994`\n- `Vomiting 927`\n- `CUMULATIVE as of openFDA pull 2026-07-22`\n- `\"Lack of efficacy\" terms denote product-performance reports, not adverse reactions`\n- `reported ≠ causal`\n","sources":["Derived plain-language — Dirlotapide withdrawal and US adverse-event record — plain-language owner summary (retrieved 2026-08-16)"],"source":{"authority":"Derived plain-language","title":"Dirlotapide withdrawal and US adverse-event record — plain-language owner summary","url":"","retrieved":"2026-08-16","ref":"","doc_type":"official source","source_document":"Dirlotapide withdrawal and US adverse-event record — plain-language owner summary","verification_file":"web/articles/articles/dirlotapide-withdrawal-ade.md"},"source_document":"Dirlotapide withdrawal and US adverse-event record — plain-language owner summary","source_file":"web/articles/articles/dirlotapide-withdrawal-ade.md","trust":{"authority_tier":"ungraded","fidelity":"verbatim","license":"derived","display_grade":"pending"},"tokens_estimated":400,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}